Natalizumab
Customize your policy alerts
Sign up for Aetna Policy 0751 alerts
Get alerted when Policy 0751 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage and utilization management criteria for natalizumab (Tysabri and biosimilar Tyruko) for Crohn's disease and relapsing forms of multiple sclerosis, including precertification and site-of-care notes, for Aetna commercial medical plans.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.